Andere Sprachen Daewoong Pharmaceutical Co., Ltd

Aktien

A069620

KR7069620003

A069620

Schlusskurs Korea S.E. Andere Börsenplätze 00:00:00 28.06.2024			% 5 Tage	% 1. Jan.
102’400 ^KRW	+0.89%		+0.20%	-12.33%

14.05.	Daewoong Pharmaceutical Co., Ltd berichtet über die Ergebnisse für das erste Quartal bis zum 31. März 2024	CI
24.04.	Koreanische Zuckerimporte brechen um 14% ein, da Diabetesfälle zunehmen	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Daewoong Pharmaceutical : Presents Enavogliflozin’s Phase 3 Pooled Analysis Results at 84th ADA Conference	19.06.
Daewoong Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Daewoong Pharmaceutical : Reports Q1 2024 Financial Results	30.04.
Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	24.04.
AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd	12.04.
AEON Biopharma, Inc. announced that it expects to receive $15 million in funding from Daewoong Pharmaceutical Co., Ltd	19.03.
Daewoong Pharmaceutical Secures Approval for Stem Cell Processing Facility in Indonesia	15.02.
Daewoong Pharmaceutical : and Zydus Announce Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S.	11.12.
Zydus Worldwide DMCC and Daewoong Pharmaceutical Co., Ltd. Announces Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S	11.12.
Daewoong Pharmaceutical : Strikes a $60 Million Deal with JSC Pharmasyntez for Diabetes Novel Drug Enavogliflozin	06.12.
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA	28.11.
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.
Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative GLP-1 Obesity Treatment with Advanced Microneedle Technology for Sustained Weekly Efficacy	07.11.
P.T. Selatox Bio Pharma announced that it expects to receive IDR 200 billion in funding from Daewoong Pharmaceutical Co., Ltd	27.10.23
Daewoong Pharmaceutical : announces ‘3E Global Hyper-Competitive Strategy' at CPHI 2023... Aiming for USD 745M in novel drug sales by 2030	26.10.23
Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023, Showcasing Own Novel Drug in the Global Market	19.10.23
Daewoong Therapeutics Gets Mfds Nod for Phase 1 Ind for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema	25.09.23
Hyphens Pharma Unit to Distribute Daewoong Pharmaceutical's Nabota Botox in Malaysia	30.08.23
Hyphens Pharma International Limited Announces Successful Registration in Malaysia	30.08.23
Daewoong Pharmaceutical : Initiates Global Export of 'Novel Drug'...Launches 'Fexuprazan' in the Philippines	17.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Daewoong Pharmaceutical Co., Ltd

Aktien

A069620

KR7069620003

A069620

Andere Sprachen

Filter